

1 **Efficacy of antibiotic and non-antibiotic interventions in preventing and**
2 **treating necrotic enteritis in broiler chickens: a protocol for a systematic**
3 **review**

4 Irene Bueno¹, Emily Smith¹, Haejin Hwang¹, Andre J. Nault², Robert Valeris-Chacin¹, Randall
5 S. Singer^{1*}

6 1. Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine,
7 University of Minnesota, Saint Paul, MN. 2. Veterinary Medical Library, College of Veterinary
8 Medicine, University of Minnesota, Saint Paul, MN.

9 *Corresponding author: Randall S. Singer (rsinger@umn.edu).

10 1971 Commonwealth Avenue, St. Paul, MN 55108.

11 **Running title:** Non-antibiotic interventions for necrotic enteritis in broiler chickens

12 **Abstract**

13 Necrotic enteritis is one of the most common and economically important bacterial diseases
14 affecting the broiler industry. Limitations on the use of antimicrobials have highlighted the need
15 to evaluate the efficacy of non-antibiotic alternatives and management strategies. However, the
16 available evidence on the efficacy of non-antibiotic interventions for necrotic enteritis has not
17 been systematically synthesized. Here we present a protocol to conduct a systematic review of
18 the literature to assess the efficacy of non-antibiotic interventions compared to antibiotic
19 interventions in preventing and treating necrotic enteritis cases in broiler chickens.

20

21 **Keywords:** poultry, antibiotics, *Clostridium spp*, systematic review, enterotoxemia

22 **Introduction**

23 **Rationale**

24 Necrotic enteritis (NE) is a poultry disease that mostly affects broiler chickens between 3-4
25 weeks of age, and is primarily caused by types A and C toxins produced by pathogenic strains of
26 *Clostridium perfringens* (Mwangi et al., 2019, Singer and Porter, 2019, Opengart and Boulianne,
27 2020). There are two presentations of NE: a clinical form, characterized by acute onset, mortality
28 rates of up to 50%, and necrosis of the small intestine mucosa; and a subclinical form,
29 characterized by reduced weight gain, decreased digestion, and increased feed conversion ratio
30 (Yegani and Korver, 2008, Opengart and Boulianne, 2020). This disease has a large impact on
31 the poultry industry, with estimated economic losses of \$2 billion worldwide annually
32 (McReynolds et al., 2004, Moore et al., 2016, Cooper and Songer, 2016).

33
34 There are several risk factors that have been associated with NE outbreaks. Incidence or co-
35 infection with coccidiosis is a main predisposing factor, but diets that are poorly digestible or
36 high in protein, as well as slow gastrointestinal tract transit time can also increase the risk of NE
37 (Yegani and Korver, 2008, Moore et al., 2016, Khalique et al., 2020, Opengart and Boulianne,
38 2020). Therefore, reducing the exposure to these risk factors may help prevent and control
39 necrotic enteritis.

40
41 The broiler industry has historically used antibiotics and coccidiostatic drugs to control NE and
42 to improve the overall health and growth of chickens (Dibner and Richards, 2005, McEwen and

43 Fedorka-Cray, 2002, Opengart and Boulianne, 2020). In fact, NE is one of the two most
44 important diseases of chickens requiring antimicrobial therapy in the U.S. (Singer and Porter,
45 2019). However, due to rising concerns about potential emergence of antimicrobial resistance
46 and its public health implications, veterinarians and poultry producers have made changes to
47 their antimicrobial use practices. In addition, changes to antimicrobial policy have been instituted
48 at the national level. For instance, the European Union eliminated the use of antimicrobial
49 growth promoters (AGP) in 2006 (Cooper and Songer, 2016). More recently, the United States
50 Food & Drug Administration (FDA) made several key changes to antimicrobial policy. In FDA
51 Guidance for Industry (GFI) documents #209 and #213 (FDA, 2012, FDA, 2013), medically
52 important antimicrobials in food-producing animals were limited to those situations deemed
53 necessary for assuring animal health. Drug sponsors voluntarily removed label claims relating to
54 production uses (growth promotion/feed efficiency) of medically important antimicrobials,
55 thereby eliminating the use of medically important antimicrobials for growth promotion in U.S.
56 animal agriculture.

57
58 After antimicrobial growth promoters (AGP) were eliminated in the E.U. in 2006, the incidence
59 of NE increased significantly in some European countries (Cooper and Songer, 2016). With
60 changes in antimicrobial use practices, the U.S. industry will likely face new challenges to
61 control diseases as well. Therefore, it is critical to investigate the efficacy of non-antibiotic
62 alternatives as they compare to the efficacy of antibiotics in preventing, treating and controlling
63 infectious diseases in broiler production, including NE. To date, such an assessment has been
64 done to evaluate the efficacy of antibiotics (but not the efficacy of non-antibiotic alternatives) to
65 control colibacillosis in broilers in the form of a systematic review. In that study, the authors did

66 not find compelling evidence for or against the efficacy of antibiotics (Sargeant et al., 2019).
67 However, as the authors note, there were only nine studies included in the final analysis (out of
68 more than 3,000 publicly available papers evaluated), and these studies had poor reporting of key
69 design and methodological features that are essential to evaluate the internal validity of the
70 research, making it unfeasible to draw any sound conclusions (Sargeant et al., 2019). For
71 necrotic enteritis specifically, there is anecdotal evidence of the potential utility of non-antibiotic
72 alternatives such as prebiotics, probiotics, and organic acids to prevent, treat, and control the
73 disease in broilers (Caly, 2015, Cooper and Songer, 2016, Khalique, 2020). However, a
74 comprehensive critical appraisal of the evidence is still lacking.

75

76 Systematic reviews (SR) are rigorous scientific methods of research synthesis conducted in a
77 transparent and reproducible manner (Sargeant and O'Connor, 2020). In addition, SR are useful
78 in identifying knowledge gaps pertaining to a specific research question. We will conduct a
79 systematic review to evaluate the efficacy of non-antibiotic interventions as they compare to
80 antibiotic interventions as a disease management approach for necrotic enteritis in broiler
81 chickens.

82 **Objectives**

83 Our goal is to conduct a systematic review of the literature to critically evaluate the available
84 evidence on the following research question: *What is the efficacy of non-antibiotic interventions,*
85 *compared to antibiotic interventions, in preventing and treating necrotic enteritis in broiler*
86 *chickens?* The purpose of this protocol is to describe a methodology to perform a systematic
87 review that addresses this question. The methodology follows the guidelines from PRISMA-P
88 (Moher et al., 2015).

89 **Methods**

90 An appropriate review team will be composed of six members and will include expertise on
91 poultry disease management, microbiology, epidemiologic methods, systematic review methods,
92 and indexing and databases.

93 **Eligibility criteria**

94 The criteria used for eligibility for this systematic review will be based on the PICOS
95 (Population, Intervention, Comparator, Outcome, Study design) framework (Sargeant and
96 O'Connor, 2020), and the details can be found in Table 1.

97 **Information sources**

98 The following electronic databases will be searched with no language or date restrictions:
99 PubMed/MEDLINE, CAB Abstracts, Agricola, and Scopus. The search strategy to be conducted
100 for each database is detailed below. In addition to the electronic databases, hand searches of key
101 review papers as well as gray literature on necrotic enteritis will be conducted.

102 **Search strategy**

103 For PubMed/MEDLINE, the search string will be: (*"Chickens"[Mesh]*) AND (*"Enteritis/diet*
104 *therapy"[Mesh]* OR *"Enteritis/drug therapy"[Mesh]* OR *"Enteritis/prevention and*
105 *control"[Mesh]*), where 'Mesh' represents the appropriate Medical Subject Heading term.

106 For CAB Abstracts and Agricola, both of which can be searched with the OVID search interface,
107 the search string will be: (*chicken* and enteritis and (protection or control or treatment)*).af.,
108 where 'af' represents all fields of the record.

109 Lastly, for Scopus: *chicken* AND enteritis AND (protection OR control OR treatment)*.

110 **Study records**

111 *Data management*

112 Database records of the articles retrieved by the searches will be imported into EndNote X8
113 (Thomson Reuters) and duplicate records will be removed. Relevance screening, design
114 screening, data extraction, and risk of bias assessment will be recorded in Microsoft Excel 2016
115 (Microsoft Corporation, Redmond, WA, USA). Statistical analyses (if needed) will be performed
116 in R 3.6.2 (R Core Team, 2019).

117 *Selection process*

118 There will be two stages of screening for the citations: 1) relevance screening and 2) design
119 screening. During the first stage, titles and abstracts will be screened by two independent
120 reviewers, and articles that are not relevant to the review question will be excluded. Conflicts
121 between the two reviewers will be discussed until consensus is achieved, or with the help of a
122 third reviewer. Relevance screening questions will be as follows:

123 a) Does the title/abstract describe a primary research study or a conference proceeding (as
124 opposed to reviews, theses, and book chapters)?

125 b) Does the title/abstract refer to necrotic enteritis or to *Clostridium perfringens*?

126 c) Does the title/abstract refer to broiler chickens?

127 Answers to these questions will be 'Yes', 'No', or 'Unclear' ('Unclear' will be used when the
128 answer to the relevance screening questions cannot be determined solely by the title/abstract).

129 Articles will be excluded if the answer to at least one of the relevance screening questions is
130 'No'. Articles where the answers to all the questions are 'Yes', 'Unclear', or a combination of

131 'Yes' and 'Unclear' will be included and evaluated in the second screening stage. The full text of
132 all the articles included during relevance screening will be retrieved. For any conference
133 proceedings, an effort will be made to contact the corresponding author to obtain a copy of the
134 article if the full text cannot be retrieved.

135 During the second screening stage, design screening, only the methods section of the full-text
136 will be reviewed. Two independent reviewers will screen these studies, and discrepancies will be
137 resolved between the two reviewers, or with the help of a third reviewer. Design screening
138 questions will be as follows:

139 a) Is the study design an *in vivo* experiment or an observational study of these designs: cross-
140 sectional, cohort, case-control, ecological? *In vitro* and *in silico* (simulations) studies, case series,
141 and case reports will be excluded.

142 b) Does the study have a comparison group?

143 c) Does the study include quantifiable outcomes associated with NE disease in broiler chickens?

144 Answers to these questions will be 'Yes', 'No', or 'Unclear'. Studies will be included only if
145 they receive 'Yes', 'Unclear' or a combination of the two to all questions. Studies for which the
146 answer to at least one of the questions is 'No' will be excluded. Both stages of the screening
147 process (relevance and design screening) will be tested *a priori* with a random group of articles
148 that result from the search. An effort will be made to translate full-text of articles that are not in
149 English within the review team capabilities. If the full text cannot be translated into English, it
150 will be excluded.

151 **Data extraction**

152 Data from the final set of included studies will be captured in a spreadsheet form and will
153 include the following information: general study characteristics (geographic location, year the
154 study took place), study design details including sample size, animal characteristics (breed, age,
155 housing/experimental conditions), intervention type and level of the intervention (farm, house,
156 individual), statistical methods, any covariates used for confounding adjustment, effect
157 measure(s) (or test statistics), measures of variability, *P* values, necrotic enteritis
158 detection/diagnostic method(s), and outcome(s) information. Two reviewers will independently
159 extract data from the included studies, and a third reviewer will validate the data entry. The data
160 extraction form will be pretested by all reviewers and improved accordingly.

161 **Risk of bias assessment**

162 All included studies will be evaluated for threats to internal validity in three domains:
163 information bias, selection bias, and confounding. Two independent reviewers will assign a
164 qualitative rubric of low, high, and unclear to each one of the domains for each one of the
165 studies, using their judgment. An overall risk of bias based on the individual domain scores will
166 be determined by assigning the worst risk of bias in any of the domains. For example, if a study
167 were considered to have a high risk of information bias, unclear risk of selection bias, and low
168 risk of confounding, the overall risk of bias would be high risk. Any disagreements between
169 reviewers will be discussed until they reach consensus, or with the help of a third reviewer. This
170 approach is being adapted from the Cochrane Collaboration Risk of Bias Tool used to assess risk
171 of bias in randomized trials in human subjects (Sterne et al., 2019).

172 Results for the risk of bias will be recorded in a spreadsheet form, which will be tested *a priori*
173 by the reviewers and improved accordingly. Broadly, low risk of bias refers to studies where bias
174 is unlikely to alter the results of that study; unclear risk of bias refers to studies where there is not

175 enough information to determine if bias would influence the results; and high risk of bias refers
176 to studies where it is very likely that the results would be altered due to bias. What follows is a
177 brief definition of each type of bias that will be evaluated with examples for each one of the
178 qualitative categories (low, unclear, and high).

179 Information bias is an error that arises from the systematically different way the exposure(s) and
180 outcome(s) are measured between the groups that are being compared (Aschengrau and Seage,
181 2020). Examples of low, high, and unclear risk of information bias follow.

182 Low risk of information bias: in a randomized trial, farm personnel were blinded to treatment
183 allocation.

184 High risk of information bias: in a randomized trial, farm personnel were not blinded to
185 treatment allocation and *Clostridium perfringens* isolation and identification from chicken
186 samples was conducted in two different laboratories.

187 Unclear risk of information bias: researchers did not provide information on the blinding process
188 of the farm personnel, and there was no information about quality assurance in the paper.

189 Selection bias (also referred to as collider stratification bias, Hernan and Robins, 2020) results
190 from systematic differences between characteristics of the subjects available for analysis and the
191 population from which they were drawn (Thrusfield, 2018). Examples of low, high, and unclear
192 risk of selection bias follow:

193 Low risk of selection bias: broilers were randomly selected for an experimental study where one
194 group received a nutritional supplement (treatment group) and the other group did not (control
195 group). Both groups were selected from the same poultry farm and had the same exact baseline
196 characteristics as they were selected into the study (age, weight, husbandry conditions).

197 High risk of selection bias: broilers were randomly selected for an experimental study where one
198 group received nutritional supplement (treatment group) and the other did not (control group).
199 The treatment group was selected from one poultry company and the control group was selected
200 from a different poultry company. These companies had different husbandry conditions.

201 Unclear risk of selection bias: broilers were randomly selected for an experimental study where
202 one group received nutritional supplement (treatment group) and the other did not (control
203 group). There were no details about the target population that generated the experimental groups.

204 Confounding occurs due to a failure of the comparison group to reflect the counterfactual ideal
205 of the exposed group (Aschengrau and Seage, 2020). Examples of low, high, and unclear risk of
206 confounding follow:

207 Low risk of confounding: randomized trial with broiler chicken farms randomized into treatment
208 (prebiotic) or control (antibiotic) groups. The number of farms in the study was more than 30.

209 High risk of confounding: cohort study of two broiler chicken farms, where Farm A administered
210 prebiotics and was compared to Farm B, which administered antibiotics. Farm A vaccinated
211 against coccidiosis while Farm B did not. Researchers did not adjust for this other factor in their
212 analyses.

213 Unclear risk of confounding: cohort study of broiler chicken farms with some farms using
214 prebiotics and other farms using antibiotics. Researchers adjusted in their analyses for potential
215 confounders such as nutritional supplement given in some farms and not others, but did not
216 mention or included other potentially important confounders (e.g. season).

217 **Evidence synthesis**

218 The available evidence addressing the research question will be synthesized narratively, and a
219 meta-analysis will be conducted to provide summary effect measures if there are sufficient data
220 from quantitative and homogeneous studies to permit such a statistical analysis. Additionally,
221 publication bias will be evaluated using funnel plots where possible (Sargeant and O'Connor,
222 2020).

223 **Discussion**

224 The current protocol lays out the methodology that will be used to conduct a systematic review
225 of the literature to assess the efficacy of non-antibiotic alternatives in the management of
226 necrotic enteritis in broiler chickens. Any deviations from this protocol will be stated in the final
227 systematic review manuscript. The results from the systematic review will prove useful for
228 poultry veterinarians and managers, as it will summarize the available evidence as well as the
229 information gaps on this important topic.

230 **Acknowledgements**

231 This work was supported by grant no. 2015-68003-22972 from the USDA National Institute of
232 Food and Agriculture. Any opinions, findings, conclusions, or recommendations expressed in
233 this publication are those of the authors and do not necessarily reflect the view of the U.S.
234 Department of Agriculture.

235

236

237

238

239 **References**

- 240 1. Aschengrau A, and Seage GR (2020). Bias. In: Aschengrau A and Seage GR III (Eds)
241 Essentials of Epidemiology in Public Health. Fourth ed.: Jones & Bartlett Learning, pp. 544-
242 590.
- 243 2. Caly DL, D'Inca R, Auclair E, and Drider D (2015). Alternatives to antibiotics to prevent
244 necrotic enteritis in broiler chickens: a microbiologist's perspective. *Frontiers in*
245 *Microbiology* 6:1336. doi: 10.3389/fmicb.2015.01336.
- 246 3. Cooper KK, and Songer JG (2016). Necrotic enteritis of poultry. In: Uzal FA (Ed) *Clostridial*
247 *Diseases of Animals*. John Wiley & Sons, Inc, pp. 123-137.
- 248 4. Dibner JJ, and Richards JD (2005). Antibiotic growth promoters in agriculture: history and
249 mode of action. *Poultry Science* 84(4):634-643.
- 250 5. Hernan MA, and Robins JM (2020). *Causal inference: What if*. Boca Raton: Chapman &
251 Hill/CRC.
- 252 6. Khalique A, Zeng D, Shoaib M, Wang H, Qing X, Rajput DS, ... and Ni X (2020). Probiotics
253 mitigating subclinical necrotic enteritis (SNE) as potential alternatives to antibiotics in
254 poultry. *AMB Express* 10(1): 1-10. <https://doi.org/10.1186/s13568-020-00989-6>.
- 255 7. McEwen SA, and Fedorka-Cray PJ (2002). Antimicrobial use and resistance in animals.
256 *Clinical Infectious Diseases* 34(3): S93–S106. <https://doi.org/10.1086/340246>.
- 257 8. McCreynolds J, Byrd J, Anderson R, Moore R, Edrington T, Genovese K, Poole T, Kubena L,
258 and Nisbet D (2004). Evaluation of immunosuppressants and dietary mechanisms in an
259 experimental disease model for necrotic enteritis. *Poultry Science* 83:1948-1952.

- 260 9. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, and
261 Stewart LA (2015). Preferred reporting items for systematic review and meta-analysis
262 protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 4:1.
- 263 10. Moore RJ (2016). Necrotic enteritis predisposing factors in broiler chickens. *Avian*
264 *Pathology* 45(3):275-281. <http://dx.doi.org/10.1080/03079457.2016.1150587>.
- 265 11. Mwangi S, Timmons J, Fitz-Coy S, and Parveen S (2019). Characterization of *Clostridium*
266 *perfringens* recovered from broiler chicken affected by necrotic enteritis. *Poultry Science*
267 98(1): 128-135.
- 268 12. Opengart K, and Boulianne M (2020). Necrotic enteritis. In: Swayne DE, Glisson JR,
269 Mcdougald LR, Nolan LK, Suarez DL, and Nair VL (Eds) *Diseases of Poultry* 14th Edition,
270 John Wiley & Sons, Inc, pp 972-976.
- 271 13. Sargeant JM, Bergevin MD, Churchill K, Dawkins K, Deb B, Dunn J, ... and Novy A (2019).
272 The efficacy of litter management strategies to prevent morbidity and mortality in broiler
273 chickens: a systematic review and network meta-analysis. *Animal Health Research Reviews*
274 20(2): 247-262. <https://doi.org/10.1017/S1466252319000227>.
- 275 14. Sargeant JM, and O'Connor AM (2020). Scoping reviews, systematic reviews, and meta-
276 analysis: applications in veterinary medicine. *Frontiers in Veterinary Science* 7:11.
- 277 15. Singer RS, Porter L. Estimates of on-farm antimicrobial usage in broiler chicken and turkey
278 production in the United States, 2013 – 2017. Mindwalk Consulting Group, LLC. 2019.
279 Falcon Heights, MN, USA. Available online at:
280 http://mindwalkconsultinggroup.com/poultry_on-farm_antimicrobial_use_2013-2017.

- 281 16. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, ... and Emberson JR
282 (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 366.
283 <http://dx.doi.org/10.1136/bmj.l4898>.
- 284 17. Thrusfield M (2018). *Veterinary Epidemiology*. John Wiley & Sons, Inc.
- 285 18. U.S. Food and Drug Administration (2012). Guidance for Industry #209: The Judicious Use
286 of Medically Important Antimicrobial Drugs in Food-Producing Animals. Retrieved from
287 <http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM216936.pdf>. Last accessed May 10, 2020.
- 288
- 289 19. U.S. Food and Drug Administration (2013). Guidance for Industry #213: New Animal Drugs
290 and New Animal Drug Combination Products Administered in or on Medicated Feed or
291 Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for
292 Voluntarily Aligning Product Use Conditions with GFI #209. Retrieved from
293 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed)
294 [new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed)
295 [feed](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed). Last accessed May 10, 2020.
- 296 20. Yegani M and Korver DR (2008). Factors affecting intestinal health in poultry. *Poultry*
297 *Science* 87(10): 2052-2063. doi:10.3382/ps.2008-00091.
- 298
- 299

300 **Table 1.** Eligibility criteria for this systematic review following the PICOS framework

301 (Sargeant and O'Connor, 2020).

Population (P)	Broiler chickens
Intervention (I)	Administration of non-antibiotic interventions to prevent or treat necrotic enteritis (vaccines, probiotics, nutritional management)
Comparator (C)	Administration of antibiotics to prevent or treat necrotic enteritis
Outcome/s (O)	Mortality, clinical or subclinical NE
Study design (S)	<i>in vivo</i> experimental studies, observational studies

302

303